ArticleCase reports in oncology
Osimertinib for Uncommon Endothelial Growth Factor Receptor-Mutant Non-Small Cell Lung Carcinoma: A Case Report.
Article in Case reports in oncology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
- Erratum issued
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Non-small cell lung cancer (NSCLC) accounts for 84% of all lung cancers and continues to remain the leading cause of cancer-related mortality worldwide. The advent of gene targeted therapies has changed the landscape of NSCLC management. Osimertinib is a third-generation tyrosine kinase inhibitor (TKI) that has activity against exon 19, exon 21 (L858R) mutations. It is also active against T790M mutation which is the most common resistant mechanism to earlier generation TKIs. Activity of osimertinib against rare EGFR mutations is largely unknown. We report the case of a 64-year-old woman with metastatic NSCLC carrying an exceedingly rare deletion-insertion exon 19 EGFR mutation (p.E746_S752delinsV) who demonstrated sustained disease control with osimertinib, achieving a progression-free survival of 26 months. Case Presentation: A 64-year-old nonsmoker female presented with back pain for 1 month. Magnetic resonance imaging spine showed pathological fracture secondary to multiple lytic lesions. She underwent FDG PET/CT that showed large left lower lobe mass, bilateral pulmonary nodules, widespread osteolytic lesions. She underwent iliac lytic lesion biopsy that was consistent with adenocarcinoma (TTF1- and CK7-positive). Tumor tissue next-generation sequencing showed EGFR exon 19 mutation (DNA change: c.2237_2255delinsT, amino acid change: p.E746_S752delinsV [Glu 746_Ser752delinsval]). She was started on osimertinib and showed clinical response within 2 weeks of starting therapy. She was able to maintain a response for 26 months since starting treatment. Conclusion: In summary, there are limited prospective data to guide therapy in patients with rare EGFR mutations. Prospective studies are required to evaluate the response to endothelial growth factor receptor-tyrosine kinase inhibitors in patients with rare EGFR mutations in order to ensure patient safety and response to treatment in this patient population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.